chronic kidney disease secondary hyperparathyroidism
Conditions
Interventions
1) Patients not currently using Ca receptor agonists
Ca receptor agonists will be used for 3 months, then discontinued for 3 months. Fluctuations in iPTH Ca P will be adjusted using active vitamin D.
Sponsors
Imai Eri
Kaneko Shuzo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have been undergoing hemodialysis for more than 3 months, have secondary hyperparathyroidism, and can use Ca receptor agonists for routine medical purposes.
Exclusion criteria
Exclusion criteria: Pre-dialysis serum Ca concentration < 8.4mg/dl / Non-pregnant patients / Patients with nasal congestion / Patients with reduced saliva secretion / Patients with zinc, copper, iron, or vitamin B12 deficiency / Patients who have had COVID-19 infection within the past six months / Patients undergoing dental treatment such as tooth extraction / Patients who have suffered from head trauma, chronic otitis media, or chemotherapy within the past six months / Patients with poorly controlled diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of subjective symptoms using questionnaire method/ Taste threshold test using filter paper | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Dry weight/ nPCR | — |
Contacts
Public ContactEri Imai
Itabashi Chuo Medical Center
Outcome results
None listed